140 ( 61 % ) patients in the placebo group reported adverse events ( four [ 2 % ] severe and six [ 3 % ] serious ) , as did 123 ( 55 % ) patients in the empagliflozin 10 mg group ( eight [ 4 % ] severe and eight [ 4 % ] serious ) , 135 ( 60 % ) patients in the empagliflozin 25 mg group ( seven [ 3 % ] severe and five [ 2 % ] serious ) , and 119 ( 53 % ) patients in the sitagliptin group ( five [ 2 % ] severe and six [ 3 % ] serious ) .